## INSTRUCTIONS TO CONTRIBUTORS

- **1. Aims and Scope:** The Fukushima Journal of Medical Science is the official journal of the Fukushima Society of Medical Science and contributes to medical progress and development. The journal invites review articles, original articles, and reports on experiments and clinical cases. Significant contributions relating to basic research, theory and practice are also welcomed.
- 2. Submission of Papers: All authors are requested to submit their original manuscript and figures to the Office of Fukushima Journal of Medical Science, Fukushima Medical University Center for Academic Information Services, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1297, Japan. Tel: +81-24-547-1682, Fax: +81-24-547-1996. Electronic manuscript submission is always required. Please submit your file in PDF format to the Office at f-igaku@fmu.ac.jp by email or send CD-R includes your manuscript. Authors must complete a Conflict of Interest Statement and a Certificate of exclusive submission at the time of submission of each manuscript.

## 3. Manuscript Preparation

**Manuscripts** must be written in English, double-spaced with wide margins on one side of A4 paper. Manuscripts should follow the style of the "Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly work in Medical Journals" as published by the International Committee of Medical Journal Editors (ICMJE). For any information that is not included in this instruction, authors should refer to the ICMJE Recommendations, which are available at www.icmje.org.

Original articles are divided into the following sections: Abstract (approximately 200 words), Introduction, Materials and Methods, Results, Discussion, Acknowledgements, Conflict of Interest Disclosure (required), References and Figure Legends. The sections of review articles and case reports can be changed. The title page must comprise (1) the title, (2) the full-names of all authors, (3) their institutions, (4) running head (not exceeding 45 characters including spaces), (5) keywords (5 or less), and (6) the mailing address of the corresponding author including telephone and FAX numbers and e-mail address. An electronic copy of the paper should accompany the final version.

## **References** should be given in the following form:

- Ohira H, Iwasaki M, Takiguchi J, et al. HLA-A2-restricted cytotoxic T lymphocyte activity during interferon beta therapy in patients with chronic1hepatitis C. Fukushima J Med Sci, 48:75-83, 2002.
- Morimura Y, Watanabe T, Nishiyama H, Yamada H, Yanagida K, Sato A. Apoptosis of tumor cells and prediction of radiotherapy response in uterine cervical carcinoma. (in Japanese) Fukushima Med J, 53:21-29, 2003.
- **3.** Mollison PL, Engelfriet CP, Contreras M. Immunology of leukocytes, platelets and plasma components. *In*: Blood Transfusion in Clinical Medicine. 10th ed. Blackwell Science, Oxford, 425-458, 1997.
- 4. McDougall IR, Cavalieri RR. In vivo radionuclide tests and imaging. In: Braverman LE, Utiger

RD, eds. Werner & Ingbar's the thyroid: a fundamental and clinical text. 8th ed. Lippincott Williams & Wilkins, Philadelphia, 355-375, 2000.

Cite the names of all authors when there are six or fewer; when seven or more, list the first three authors followed by et al.

**Figures** should be clear, suitable for reproduction or reduction in size without retouching. Figures should be cited in the text and supplied figure legends. Acceptable formats are TIFF or JPEG. They should be identified with the author's name and the figure number on the back.

**Photographs** must be supplied as they are to be reproduced. A scale should be marked on the photograph, if necessary.

**Tables** should be numbered serially and given a suitable title and each table typed on a separate sheet. Footnotes to tables should be typed below the table.

## **Clinical trial Registry**

Fukushima Journal of Medical Science requires that all clinical trials should be registered on public trial registries. If the trial is the subject of the manuscript, the registration number should be included.

Example1: Registration ID: UMIN 0000112547

Example2: Registration ID: NCT 0000112547

- **4. Peer Review**: Manuscripts submitted for papers or reports will be forwarded to at least two anonymous peer reviewers to be selected by the Editorial Committee. With the reviewers' approval, the Editorial Committee makes decision on acceptance of the paper/report for publication.
- **5. Ethics**: All studies that involve human subjects must abide by the World Medical Association's Declaration of Helsinki and be approved by at least one institutional ethics committee with appropriate authority and jurisdiction. In cases where informed consent is required, it should be clearly stated that all subjects gave their informed consent prior to their inclusion in the study. Investigators should also follow guidelines for care and use of laboratory animals of their institution or national animal welfare committee.
- **6. Disclosed Potential Conflict of Interest**: When submitting a manuscript to the Fukushima Journal of Medical Science, all authors are required to disclose any financial relationship with biotechnology manufactures, pharmaceutical companies, or other commercial entity that has any interest in the subject matter, materials, or process discussed in the manuscript.
- **7. Page charge**: Member; free of charge. Not a member; ¥2,000 per printed page. The editing charge of publication data is charged. Articles requested by the Editor will be printed free of charge.
- **8.** The copyright of the articles published in the Journal is transferred from the authors to the Publisher, the Editorial Office of The Fukushima Society of Medical Science, upon acceptance of the manuscript.
- **9. Online First**: The articles will be published online after receipt of the corrected proofs.